Di Napoli Mario, Schwaninger Markus, Cappelli Roberto, Ceccarelli Elena, Di Gianfilippo Giacinto, Donati Cristina, Emsley Hedley C A, Forconi Sandro, Hopkins Stephen J, Masotti Luca, Muir Keith W, Paciucci Anna, Papa Francesca, Roncacci Sabina, Sander Dirk, Sander Kerstin, Smith Craig J, Stefanini Alessandro, Weber Daniela
San Camillo de Lellis General Hospital, Rieti, Italy.
Stroke. 2005 Jun;36(6):1316-29. doi: 10.1161/01.STR.0000165929.78756.ed. Epub 2005 May 5.
Several studies have shown, in different populations, that modest elevation of plasma C-reactive protein (CRP) in the range seen in apparently healthy individuals is a strong predictor of future vascular events. Elevated plasma CRP concentrations are also associated with an increased risk of cerebrovascular events and an increased risk of fatal and nonfatal cardiovascular events in ischemic stroke patients. These epidemiological and clinical observations suggest that determination of plasma CRP concentrations could be used as an adjunct for risk assessment in primary and secondary prevention of cerebrovascular disease and be of prognostic value. The aim of this review is to summarize the evidence for CRP as an independent predictor of cerebrovascular events in at-risk individuals and ischemic stroke patients and to consider its usefulness in evaluating prognosis after stroke.
CRP fulfils most of the requirements of a new risk and prognostic predictor, but several issues await further confirmation and clarification before this marker can be included in the routine evaluation of stroke patients and subjects at risk for cerebrovascular disease. Potentially important associations have been established between elevated plasma CRP concentrations and increased efficacy of established therapies, particularly lipid-lowering therapy with statins.
At present, there is not sufficient evidence to recommend measurement of CRP in the routine evaluation of cerebrovascular disease risk in primary prevention, because there is insufficient evidence as to whether early detection, or intervention based on detection, improves health outcomes, although shared risk of cardiovascular disease indicates this may be of value. In secondary prevention of stroke, elevated CRP adds to existing prognostic markers, but it remains to be established whether specific therapeutic options can be derived from this.
多项研究已表明,在不同人群中,血浆C反应蛋白(CRP)出现明显健康个体中所见范围内的适度升高是未来血管事件的强有力预测指标。血浆CRP浓度升高还与缺血性卒中患者脑血管事件风险增加以及致命和非致命心血管事件风险增加相关。这些流行病学和临床观察结果表明,测定血浆CRP浓度可作为脑血管疾病一级和二级预防中风险评估的辅助手段,并具有预后价值。本综述的目的是总结CRP作为高危个体和缺血性卒中患者脑血管事件独立预测指标的证据,并探讨其在评估卒中后预后方面的实用性。
CRP满足新型风险和预后预测指标的大部分要求,但在该标志物可纳入卒中患者和脑血管疾病高危受试者的常规评估之前,仍有几个问题有待进一步证实和阐明。血浆CRP浓度升高与现有治疗方法(尤其是他汀类药物降脂治疗)疗效增加之间已建立了潜在的重要关联。
目前,没有足够的证据推荐在一级预防中对脑血管疾病风险进行常规评估时检测CRP,因为关于早期检测或基于检测的干预是否能改善健康结局的证据不足,尽管心血管疾病的共同风险表明这可能有价值。在卒中二级预防中,CRP升高可补充现有的预后标志物,但能否据此得出具体的治疗方案仍有待确定。